227
Participants
Start Date
October 15, 2019
Primary Completion Date
January 15, 2025
Study Completion Date
December 31, 2025
Sacituzumab Govitecan-hziy
Administered intravenously
Cliniques Universitaires UCL Saint-Luc, Brussels
Macquarie University, North Ryde
Blacktown Hospital, Westmead
Calvary Mater Newcastle Hospital, Waratah
Southern Highlands Cancer Center, Bowral
Monash Medical Centre, Monash Health, Clayton
The Andrew Love Cancer Centre, Geelong Hospital, Geelong
Mater Cancer Centre, Mater Misericordiae Limited, South Brisbane
Pindara Private Hospital, Benowa
Lyell McEwin Hospital, Elizabeth Vale
Grand Hopital de Charleroi asbl (GHdC), Charleroi
Hospital Universitari Vall d'Hebron, Barcelona
Memorial Sloan Kettering Cancer Center, New York
Weill Cornell Medicine - Upper East Side, New York
Montefiore Medical Center, The Bronx
New York Oncology Hematology - Albany Medical Center, Albany
Centre George Francois Leclerc, Dijon
Virginia Cancer Specialists, PC, Fairfax
Blue Ridge Cancer Care - Wytheville, Blacksburg
Hospital Universitario 12 de Octubre, Madrid
Institut Claudius Régaud - IUCT Oncopole, Toulouse
Institut Bergonie, Bordeaux
Chang Gung Medical Foundation, Linkou Chang Gung Memorial Hospital, Taoyuan
Tennessee Oncology, PLLC, Nashville
North Mississippi Medical Center - Hematology and Oncology - Tupelo, Tupelo
University of Kentucky Medical Center, Lexington
University Hospitals Cleveland Medical Center, Cleveland
Hospital Clínico Universitario de Valencia, Valencia
PathGroup Labs, LLC, Fort Wayne
Parkview Research Center, Fort Wayne
University of Michigan Rogel Cancer Center, Ann Arbor
Karmanos Cancer Institute, Detroit
SIU School of Medicine, Simmons Cancer Institute at SIU, Springfield
Washington University School of Medicine - Siteman Cancer Center, St Louis
David C. Pratt Center, St Louis
Christus Highland Cancer Treatment Center, Shreveport
Highlands Oncology Group, Springdale
Texas Oncology - Tyler, Tyler
The University of Texas MD Anderson Cancer Center, Houston
University of Colorado Hospital - Anschutz Cancer Pavilion, Aurora
USOR - Arizona Oncology - Glendale - Saguaro Cancer Center, Glendale
Arizona Oncology Associates PC-HAL, Goodyear
Comprehensive Cancer of Nevada, Las Vegas
UCLA Hematology/Oncology, Los Angeles
TRIO-US Central Administration, Whittier
Institut Gustave Roussy, Villejuif
Willamette Valley Cancer Institute and Research Center - Eugene, Eugene
Providence Regional Cancer Partnership, Everett
Alaska Oncology & Hematology, LLC, Anchorage
Smilow Cancer Hospital at Yale, New Haven
Cross Cancer Institute, Edmonton
London Health Sciences Centre- Victoria Hospital, London
Jewish General Hospital, Montreal
The Ottawa Hospital, Ottawa
Hong Kong Integrated Oncology Centre, Central
Hong Kong Sanatorium & Hospital, Happy Valley
Queen Mary Hospital, Hong Kong
Hong Kong United Oncology Center, Kowloon
Department of Clinical Oncology, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin
Changhua Christian Hospital, Changhua
Taipei TzuChi Hospital, New Taipei City
Chi Mei Medical Center, Tainan City
National Cheng Kung University Hospital, Tainan City
Hospital de la Santa Creu i Sant Pau, Barcelona
Institut Català d'Oncologia, Barcelona
Lead Sponsor
Gilead Sciences
INDUSTRY